Back to A
A (Agilent) Growth, Valuation & Catalysts
$ANEUTRALHealthcare

A (Agilent) Growth, Valuation & Catalysts

Comprehensive take on Agilent ($A): solid revenue and cash flow, recent Proscia acquisition and new product launches support growth, while high multiples and limited implied upside keep the stance neutral heading into Q4 results.

November 7, 20269 min read
Current Price
$174.76
+1.73%
Analyst Rating
Strong Buy
Price Target
$174.29
-0.3% upside
P/E Ratio
34.33

Executive Summary

Investment Thesis: Agilent ($A) combines durable demand across life sciences, diagnostics and applied markets with strong margins and cash generation. Recent strategic moves, including the completed Proscia acquisition and new instrument launches, add product and software optionality to recurring consumables revenue. Valuation is elevated relative to historic averages, and analyst price targets cluster around the current share price, which reduces near-term upside. Earnings and guidance on Nov 23 will be the immediate catalyst.

Current Price: $174.76 | Key Metric: P/E 34.33 | Stance: NEUTRAL

Company Overview

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics and applied chemical markets worldwide. The business spans instruments, software and consumables used in research, drug development, clinical labs and industrial testing.

Key Products & Competitive Position

  • Core Business: Analytical instruments and services across liquid chromatography, mass spectrometry, spectroscopy, pathology and lab workflows.
  • Key Products: LC and LC/MS systems, single quadrupole MSDs like the new 5987A, consumables and CrossLab service offerings, plus recently acquired digital pathology software from Proscia.
  • Competitive Moat: Broad installed base, high consumables attach rate, integrated service revenue and strong brand recognition with global aftermarket support.

Recent Developments

Agilent announced completion of the Proscia acquisition on Nov 4, 2026, adding digital pathology and software capabilities. The company also launched the 5987A MSD with GC Assist on Nov 2. Institutional activity included Boston Trust Walden trimming its position, per a Nov 6 13F filing. Management has delivered recent quarterly beats, and Q4 fiscal 2026 results on Nov 23 will be closely watched for guidance updates.

Financial Snapshot

Market Cap$49.28B
P/E Ratio34.33
52-Week Range$108.35 - $182.99
Dividend Yield0.58%
EPS (TTM)$5.11
ROE20.47%

Revenue & Earnings Trends

Trailing revenue is about $7.37 billion, with EBITDA roughly $2.08 billion and free cash flow near $1.06 billion. Revenue growth is running in the mid single digits, roughly 8% year over year per recent data, while earnings growth is about 8.5%. Gross margins are strong at roughly 54 percent, reflecting a high-margin mix of consumables and software. Consistent service revenue from CrossLab helps stabilize recurring top line components.

Balance Sheet Highlights

Agilent carries total cash near $1.76 billion versus total debt about $4.15 billion, for net debt of roughly $2.39 billion. The current ratio is a healthy 2.05, and debt to equity sits around 56 percent. Liquidity and operating cash flow, which was about $1.61 billion, support ongoing R&D, share activity and M&A like the Proscia deal.

Valuation Analysis

Current Valuation Metrics

Forward P/EN/Avs Industry: ~25-30
PEG Ratio~4.0Growth-adjusted
EV/EBITDA~24.9vs Historical: lower
P/S Ratio~6.7vs Peers: premium

Historical Comparison

Current P/E of 34.3 sits above what many investors have paid historically for Agilent, where five year averages tended to be lower in the mid 20s. EV/EBITDA near 25 is elevated versus the companys own historical range. The premium reflects strong profitability, durable consumables economics and investor preference for secular life sciences exposure in recent years.

Fair Value Estimate

Combining multiple approaches yields a fair value zone that centers near the current price. Analyst mean targets cluster at about $174.3 while consensus highs reach $195 and lows $150. A midpoint fair value of roughly $170 to $180 reflects a balance of steady cash flows against limited near-term valuation cushion. A downside scenario with slower lab spending would push implied fair value toward the low $150s, while sustained margin expansion and faster revenue growth would justify higher multiples.

Competitive Landscape

Market Position

Market Share: Not formally disclosed in aggregate, but Agilent is a top tier provider across chromatography and mass spec segments | Ranking: Top 3 in many instrument categories

Key Competitors

Thermo Fisher Scientific (TMO)Thermo Fisher Scientific, large diversified lab products and services leader
Danaher (DHR)Danaher, broad life sciences tools and diagnostics portfolio
Waters (WAT)Waters Corp, specialist in liquid chromatography and related consumables

Competitive Advantages

  • Moat 1: Installed base and high-margin consumables create recurring revenue streams.
  • Moat 2: Broad product breadth across instruments, software and services which reduces single-product exposure.
  • Moat 3: Global service footprint via CrossLab improves switching costs for customers.

Earnings Track Record

Last 4 Quarters: 3 beats / 1 miss

Recent Earnings History

Q3 2026$1.62 vs $1.49 estBEAT
Q2 2026Reported, growth in consumables and instrumentsBEAT
Q1 2026Reported, steady marginsBEAT
Q4 2025Reported, near term pressure in parts of Applied MarketsMISS

Guidance Trend

Management has maintained a generally constructive tone on demand for chromatography, spectroscopy and consumables even while noting pockets of variability in industrial markets. Analysts are watching whether full year guidance will be nudged higher or kept steady at the Nov 23 report. The company tends to emphasize margin sustainability and FCF conversion when framing guidance.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 3 Buy: 12 Hold: 7 Sell: 0

Price Targets

  • Low: $150
  • Mean: $174.29 (-0.3% upside)
  • High: $195

Recent Analyst Actions

Consensus remains favorable with most recent coverage categorized as Strong Buy or Buy, though a meaningful minority of analysts rate the shares as Hold. That split reflects confidence in the companys long term market position while noting limited near-term valuation cushion relative to targets.

Recent News & Catalysts

Key Developments

  • Boston Trust Walden Cuts Position: Boston Trust Walden trimmed holdings by about 20.7 percent per a Nov 6 13F filing, indicating some institutional rebalancing.
  • Q4 Earnings on Deck: Zacks highlighted expectations for continued revenue and EPS growth driven by chromatography, spectroscopy and consumables ahead of the Nov 23 print.
  • Proscia Acquisition Completed: The Nov 4 completion adds digital pathology software to Agilent's portfolio which may increase software and recurring revenue exposure.
  • New 5987A MSD Launch: The Nov 2 product launch targets faster GC/MS workflows and helps refresh the instrument pipeline.
  • Macro Commentary: Broader market commentators have cited lab and research suppliers as beneficiaries of shifting tech budgets, which can drive thematic investor interest.

Upcoming Catalysts

Next Earnings: 2026-11-23 | Key Events: Q4 fiscal 2026 results, FY guidance and commentary on Proscia integration and consumables demand

Technical Outlook

Current Price: $174.76 vs 52-Week High: $182.99 (-4.5% from high)

Trend Analysis

Price strength over the last six months has been notable, with the stock up nearly 49 percent over that period. Momentum indicators generally pointed constructive heading into the earnings window, but the run has left valuation near the high end of the range which makes the technical picture watchful as traders weigh near-term catalysts.

Key Levels

  • Resistance: $183, $195
  • Support: $170, $155

Bull vs Bear Case

Bull Case

  • Catalyst 1: Continued growth in consumables and instrument upgrades sustains top line momentum.
  • Catalyst 2: Proscia integration boosts recurring software revenue and expands pathology addressable market.
  • Catalyst 3: Strong FCF and margin durability justify premium multiples versus peers.

Bull Target: $195 (+11.7%)

Bear Case

  • Risk 1: Elevated multiples and limited implied upside leave the stock vulnerable to downgraded guidance or macro-driven lab spending weakness.
  • Risk 2: M&A integration execution for Proscia could take longer or cost more than anticipated.
  • Risk 3: Intensifying competition from larger diversified peers could pressure pricing in select product lines.

Bear Target: $150 (-14.1%)

Risks to Consider

  • Valuation Risk: Elevated P/E, EV/EBITDA and PEG indicate the market is pricing continued above benchmark growth. Any slowdown could compress multiples.
  • Competitive Risk: Large diversified competitors like $TMO and $DHR may exert pricing pressure or accelerate product cycles.
  • Macro Risk: Lab and industrial capex is sensitive to economic cycles and corporate R&D budgets. A pullback in spending would hit instrument sales more than consumables.
  • Execution Risk: Acquisitions and new product rollouts require integration and commercial execution to realize expected returns.

Bottom Line

Investment Verdict: NEUTRAL

Agilent presents a profile of steady growth, attractive margins and strong cash generation, plus strategic optionality from software and digital pathology. At the same time valuation is compressed versus upside and the next earnings release is a meaningful near-term event. Data suggests you should watch earnings and guidance carefully and weigh the tradeoff between durable fundamentals and current price levels.

Action Items for Investors

  • Long-term investors: Monitor Proscia integration and recurring revenue trends, and reassess valuation after the Nov 23 earnings and any guidance revisions.
  • Short-term traders: Watch key technical levels near $170 support and the earnings print on Nov 23 for volatility that can create trading opportunities.
  • Risk management: Consider position sizing that reflects elevated multiples, and use stop management and diversification to limit single name exposure.

What to Watch This Week

  • Q4 fiscal 2026 earnings and management guidance, 2026-11-23
  • Any additional analyst revisions to price targets following the earnings print
  • Newsflow on Proscia integration milestones and consumables demand trends

Share this report

Share this article

Spread the word on social media

Think A will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.